Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2023-09-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
关于部分募集资金专户完成销户的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Tian Kang Biological Co., Ltd. regarding the closure of certain special accounts for raised funds from a previous non-public stock issuance. It details the background of the fundraising, the management and storage of the funds, the status of the special accounts, and the recent decision to close some of these accounts after project completion and fund reallocation. The document includes references to regulatory approvals, bank accounts, and board and shareholder meeting approvals. It is a formal disclosure about the status and management of fundraising accounts rather than a full financial report or audit. The document length is 2729 characters, which is relatively short and focused on a specific announcement. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-14 Chinese
关于2023年8月份生猪销售简报
Regulatory Filings Classification · 90% confidence The document is a sales briefing for August 2023 from Tian Kang Biological Co., Ltd., detailing monthly and cumulative sales volumes and revenues of live pigs. It includes sales data, reasons for sales changes, risk warnings, and a disclaimer that the data is unaudited and for investor reference only. The document is short (1841 characters) and does not contain comprehensive financial statements or detailed financial analysis. It is a periodic sales update rather than a full interim or annual financial report. It is not an earnings release since it provides detailed sales data rather than just key highlights. It is not a regulatory filing or announcement of a report publication. The document fits best as a Capital/Financing Update (CAP) type because it provides operational sales data relevant to investors and market participants, updating on business performance metrics that impact capital markets. However, since it is a sales briefing and not a financing or capital structure change, the closest category is Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories. Given the document's nature and length, Regulatory Filings (RNS) is the most appropriate classification with high confidence.
2023-09-08 Chinese
关于2023年半年度募集资金存放与实际使用情况专项报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023 年半年度募集资金存放与实际使用情况专项报告" which translates to "2023 Semi-Annual Special Report on the Deposit and Actual Use of Raised Funds." It details the use and management of funds raised through convertible bonds and private stock issuance, including amounts raised, usage, remaining balances, project progress, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed financial data on fundraising and fund usage for the half-year period ending June 30, 2023. This is a comprehensive report on the use of capital raised by the company during a half-year period, containing substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR), as it is a comprehensive financial report for a period shorter than a full fiscal year and contains actual financial statements and substantive financial data and analysis related to fundraising and capital usage. H1 2023
2023-08-25 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "天康生物股份有限公司2023 年半年度报告全文" which translates to "Tian Kang Biology Co., Ltd. 2023 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, business overview, financial metrics, and other comprehensive information typical of an interim or quarterly report. The report covers the period from January 1, 2023 to June 30, 2023, which is a half-year period. The length of the document is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content includes financial statements, management analysis, segment revenue breakdown, and other substantive financial data. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese
2023年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "天康生物股份有限公司2023 年半年度财务报告" which translates to "Tiankang Biological Co., Ltd. 2023 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2023. The report explicitly states it is a half-year report and includes comprehensive financial data and analysis for the period. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Tian Kang Bio Co., Ltd. regarding the approval of the company's 2023 semi-annual report and a special report on the use of raised funds. It references the actual semi-annual report and the special report as being published elsewhere (in a newspaper and on a website). The document itself does not contain the full financial statements or substantive financial data but rather announces the approval and legality of these reports. The document length is short (1066 characters) and serves as an official meeting resolution announcement rather than the report itself. According to the 'Menu vs Meal' rule, this is not the interim/quarterly report (IR) itself but an announcement related to it. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for such announcements that do not fit other categories.
2023-08-25 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.